Form 4: Organon Executive Reports Equity Vesting and New Grant

Vittorio Nisita, Head of Global Business Services at Organon & Co., reported the vesting of restricted stock units and a new equity grant in a Form 4 filing.

Summary

• Vittorio Nisita, Head of Global Business Services, acquired 13,000 shares of common stock through the vesting of restricted stock units (RSUs) on March 31, 2026.
• A total of 4,453 shares were withheld to cover tax obligations related to the vesting, resulting in a net increase in beneficial ownership.
• The reporting person was granted a new award of 125,208 RSUs on March 31, 2026.
• The new RSU grant is scheduled to vest in three equal annual installments starting March 31, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation and equity ownership, carrying no material impact on company operations.

Positives

• The executive maintains a significant equity stake in the company, totaling 70,619.158 shares following the transactions.
• The new RSU grant aligns executive compensation with long-term shareholder value through a three-year vesting schedule.

Negatives

• The company withheld 4,453 shares to satisfy tax withholding requirements associated with the RSU vesting.

Risks

• Future vesting of equity is subject to continued employment and potential performance conditions associated with the RSU plan.

Future Outlook

The new RSU grant of 125,208 units will vest in three equal installments on March 31, 2027, 2028, and 2029, contingent upon continued service.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive equity compensation, which is standard practice for large-cap pharmaceutical companies to ensure alignment between management and shareholders.

Comparison to Industry Standards

• The use of three-year graded vesting for RSUs is consistent with standard executive compensation practices at peer pharmaceutical firms like Merck, Pfizer, and Viatris.

Stakeholder Impact

• Shareholders should note the dilution impact of the new RSU grant, though it is within standard compensation parameters.

Next Steps

• Vesting of the first installment of the new RSU grant on March 31, 2027.

Key Dates

Keywords

Organon, OGN, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Executive Compensation